Proteomics raises A$3.0 million via a heavily oversubscribed Placement
The Placement received strong demand from new and existing institutional, family office,
sophisticated and professional investors
The capital raised will be primarily applied to:
Successful capital raising leaves Proteomics well-funded into CY20 and beyond and importantly gives the Company a strong balance sheet for any potential future licensing/partnering discussions around PromarkerD.